Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Study sponsor: Vanda Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-03Estimated
Enrollment · participants500Estimated
Source updated2026-09-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.